Aripiprazole

Active ingredient description

It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Aripiprazole
N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AX Other antipsychotics
Discover more medicines within N05AX12

Medicines

Aripiprazole is the active ingredient of these drugs:

Drug
Countries

Italy Tunisia

Spain

Australia Austria Canada Cyprus Estonia

Poland

South Africa

Australia

Spain

Brazil

Spain

Cyprus

Poland

Poland

South Africa

Estonia Lithuania

South Africa

Poland

Estonia Lithuania Poland

Austria

Germany

Poland

Germany

Hong Kong

Poland

Estonia Lithuania

Brazil

United States

South Africa

Spain

Brazil

Cyprus Germany

Poland

Germany United Kingdom

Poland

Hong Kong Poland

Poland

Spain

Brazil

Brazil

Cyprus

Poland

Brazil

Brazil

Brazil

Estonia Lithuania

Cyprus

Poland

South Africa

Brazil

Australia

Brazil

Spain

South Africa

South Africa

Cyprus Estonia Lithuania Spain

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

82VFR53I78 - ARIPIPRAZOLE

CAS registry number

129722-12-9 - aripiprazole

SNOMED-CT

406784005 - Aripiprazole (substance)